The Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why

Endpoints NewsLilly points to low-dose Zepbound and Foundayo as weight loss maintenance options

IlluminaThe Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why - simplywall.st

FierceBiotechFDA Commissioner Marty Makary to resign, capping turbulent tenure: report

FierceBiotechKyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis

Clinical OMICsLow‑Dose Digoxin Shows Benefit in Heart Failure Treatment

Clinical OMICsAntibody Promotes Nerve Regeneration in Spinal Cord Injury Patients

Clinical OMICsSingle Procedure Reduces Colorectal Cancer Risk Decades Later

10x Genomics News10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property Review

Clinical OMICsFirst Clinical Trial for a GLP-1 Gene Therapy Greenlit in Europe

BioPharma DiveFDA chief Marty Makary resigns from agency, ending tumultuous tenure

Endpoints NewsEU reaches provisional deal on Critical Medicines Act

Endpoints NewsFDA Commissioner Makary to resign, source says